1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  02:00 2022-07-05 am EDT
2125.00 JPY   +1.41%
06/28Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma
DJ
06/27Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
AQ
06/27Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
2151.5(c) 2115(c) 2058.5(c) 2095.5(c) 2125 Last
8 173 000 7 866 700 6 149 000 3 378 900 3 480 700 Volume
-2.07% -1.70% -2.67% +1.80% +1.41% Change
More quotes
Estimated financial data (e)
Sales 2022 1 320 B 9 728 M 9 728 M
Net income 2022 177 B 1 307 M 1 307 M
Net cash position 2022 340 B 2 507 M 2 507 M
P/E ratio 2022 22,3x
Yield 2022 2,39%
Sales 2023 1 434 B 10 568 M 10 568 M
Net income 2023 213 B 1 569 M 1 569 M
Net cash position 2023 350 B 2 579 M 2 579 M
P/E ratio 2023 17,9x
Yield 2023 2,86%
Capitalization 3 829 B 28 215 M 28 215 M
EV / Sales 2022 2,64x
EV / Sales 2023 2,43x
Nbr of Employees 14 522
Free-Float 98,9%
More Financials
Company
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%). 
Sector
Pharmaceuticals
Calendar
08/01Earnings Release
More about the company
Ratings of Astellas Pharma Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about ASTELLAS PHARMA INC.
06/28Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma
DJ
06/27Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Nove..
AQ
06/27Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas
DJ
06/27Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late..
AQ
06/26Astellas Pharma Inc. Announces FDA Update on Fortis Clinical Trial of AT845 in Adults w..
CI
06/23WE PUBLISHED A STORY : “Astellas' Path to Sustainability Vol.1: A New Materiality Ma..
PU
06/23ASTELLAS' PATH TO SUSTAINABILITY VOL : A New Materiality Matrix as a Compass to Direct our..
PU
06/23Astellas Submits Fezolinetant New Drug Application to U.S. FDA
CI
06/08Astellas Pharma Inc. Celebrates Opening of Large-Scale Gene Therapy Manufacturing Facil..
CI
06/02Nikkei 225 Down 0.2% on Wall Street Cues, Central Bank Outlooks
MT
06/02Japan's Nikkei edges back from 6-week high as Astellas, Sony drag
RE
06/01Japan's Nikkei retreats from 6-week high as Astellas, Sony drag
RE
05/25ASTELLAS PHARMA : Posted Notice of Convocation of the 17th Term Annual Shareholders Meetin..
PU
05/25ASTELLAS PHARMA : Notice of Convocation of the 17th Term Annual Shareholders Meetingᦀ..
PU
05/24Amphastar Pharmaceuticals Secures FDA Approval for Regadenoson
MT
More news
News in other languages on ASTELLAS PHARMA INC.
06/26Astellas Pharma Inc. Annonce une mise à jour de la FDA sur l'essai clinique Fortis de l..
06/23Astellas soumet la demande de nouveau médicament Fezolinetant à la FDA américaine
06/08Astellas Pharma Inc. célèbre l'ouverture d'une installation de fabrication de thérapie ..
06/02Nikkei 225 en baisse de 0,2% sur les indices de Wall Bourse et les perspectives des ban..
05/12Astellas Pharma Inc. met en avant les données sur les cancers avancés et rares lors de ..
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 095,50 JPY
Average target price 2 546,15 JPY
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Naoki Okamura CFO, Representative Director & Vice President
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.12.03%28 215
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782